• Skip to main content
  • Skip to footer

PeDRA

Pediatric Dermatology Research Alliance

  • DONATE
  • Pay 2022 Membership Dues
  • Join PeDRA
  • Login
MENUMENU
  • Contact Us
  • For Patients & Families
        • Patient Support
        • Patient Education
        • Community Spotlight
        • Clinical Trials
        • Patient Advisory Committee
        • Find a Pediatric Dermatologist (from SPD)
        • Parents, advocates, and patients over the age of 18 with a direct connection or significant interest in childhood skin disease or pediatric dermatology research are encouraged to join the PeDRA network for free as Community Members.

          Apply Now!

  • Education and Events
        • Virtual Education
        • Points of Discussion Podcast
        • Mentorship Program
        • Education Archive
        • 2022 PeDRA Annual Conference
        • Early Investigator Support
        • Dash for Discovery Fun Run/Walk
        • Events Calendar
        • Join PeDRA Friday, May 20th in Portland, OR for our session, Pediatric Dermatology at the 2022 SID Annual Meeting! #PeDRAatSID2022

  • Research
        • Grants & Awards
        • Resources for Researchers
        • Survey Application
        • Study Application
        • Research Areas
        • Publications
        • Clinical Trials
        • 2022 Childhood Eczema Challenge Grant applications are now being accepted with a June 1st deadline.

  • About
        • Mission & Vision
        • Leadership & Staff
        • Annual Reports & Financials
        • News Archive
        • Our Supporters
        • Our Membership
        • Our Committees
        • Getting to Know You
        • NOW HIRING! Explore current opportunities at PeDRA.

  • Member Login

Pediatric Dermatology COVID-19 Response Task Force Releases Guidance on Use of Systemic Immunosuppressive Therapy

April 24, 2020 By Mike Siegel

April 22, 2020 – Under the direction of Kelly Cordoro, MD of the University of California, San Francisco the Pediatric Dermatology COVID-19 Response Task Force (PDCRTF) has published a guidance manuscript on the use of systemic immunosuppressive therapies for inflammatory skin diseases in children.  Available on-line in the journal Pediatric Dermatology, the manuscript presents consensus-based recommendations assembled using a survey that completed by 37 experts in the field.    

With this manuscript, the PDCRTF addresses a variety of clinical scenarios, including treatment of patients with no symptoms, upper-respiratory infections without a COVID-19 diagnosis, confirmed COVID-19 exposure, and confirmed COVID-19 diagnoses. It is hoped that the paper can help inform health care providers and families making decisions to initiate or continue use of systemic oral and biologic medications for the treatment of inflammatory skin diseases in children including psoriasis, atopic dermatitis, and alopecia areata.  It also addresses issues facing front-line health care providers like lab monitoring and methods of communicating with patients and families. 

Visit the COVID-19 Information Page for other resources to support pediatric dermatologists, patients, and families during the COVID-19 pandemic.  Explore the PeDRA Publication Page for more on each of PeDRA’s peer-reviewed publications.    

Filed Under: News

Footer

  • Our Membership
  • For Patients
  • For Researchers
  • Governance Policies
  • Financial Conflict of Interest Policy
  • Jobs at PeDRA
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
Sign up to receive emails from PeDRA
Join PeDRA
Donate

Copyright © 2022 · Pediatric Dermatology Research Alliance (PeDRA) · All Rights Reserved. · Privacy Policy